Drug Profile


Alternative Names: Histone deacetylase inhibitors - Italfarmaco; ITF-2357

Latest Information Update: 19 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Italfarmaco
  • Developer Italfarmaco; Radboud University
  • Class Amines; Antineoplastics; Carbamates; Hydroxamic acids; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Juvenile rheumatoid arthritis; Polycythaemia vera
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Duchenne muscular dystrophy
  • Phase II Myeloproliferative disorders
  • Phase I/II Polycythaemia vera
  • No development reported Hereditary autoinflammatory diseases; Juvenile rheumatoid arthritis
  • Discontinued Diffuse large B cell lymphoma; Hodgkin's disease; Multiple myeloma

Most Recent Events

  • 07 Aug 2017 Italfarmaco plans a phase II trial for Duchenne muscular dystrophy (NCT03238235)
  • 01 Jun 2017 Phase-III clinical trials in Duchenne muscular dystrophy (In adolescents, In children) in Spain, United Kingdom, Belgium, USA, Italy (PO) (NCT02851797) (EudraCT2016-000401-36)
  • 13 Feb 2017 No development reported - Phase-II for Hereditary autoinflammatory diseases in Netherlands (PO) (NCT00442182)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top